References
- Aman M.G. Drugs and learning in mentally retarded persons. Advances in human psychopharmacology, Burrows G.D., Werry J.S.. JAI Press, Greenwich, CT 1984; 121–163, In
- Aman M.G. Overview of pharmacotherapy: Current status and future directions. Journal of Mental Deficiency Research 1987; 31: 121–130
- Aman M.G., Singh N.N. A critical appraisal of recent drug research in mental retardation: The Coldwater studies. Journal of Mental Deficiency Research 1986; 30: 203–206
- Aman M.G., Singh N.N., Stewart A.W., Field C.J. Psychometric characteristics of the Aberrant Behaviour Checklist. American Journal of Mental Deficiency 1985; 89(5)492–502
- Boyd R.D. Neuroleptic malignant syndrome and mental retardation: Review and analysis of 29 cases. American Journal on Mental Retardation 1993; 98: 143–155
- Fielding L.T., Murphy R.J., Reagan M.W., Petersen T.L. An assessment program to reduce drug use with the mentally retarded. Hospital and Community Psychiatry 1980; 31: 771–773
- Findholt N.E., Emmett C.G. Impact of interdisciplinary team review on psychotropic drug use with persons who have mental retardation. Mental Retardation 1990; 28: 41–49
- Glaser B.A., Morreau L.E. Effects of interdisciplinary team review on the use of antipsychotic agents with severely and profoundly mentally retarded persons. American Journal of Mental Deficiency 1986; 4: 371–379
- Intellectual Disability Review Panel. Intellectual Disability Review Panel: Report July 1988 – June 1990. Victorian Government Printer, Melbourne 1990
- Jann M.W., Ereshefsky L., Saklad S.R., Seidel D.R., Davis C.M., Burch N.R., Bowden C.L. Effects of carbamazepine on plasma haloperidol levels. Journal of Clinical Psychopharmacology 1985; 5: 106–109
- Kahn E.M., Schulz S.C., Perel J.M., Alexander J.E. Change in haloperidol level due to carbamazepine: A complicating factor in combined medication for schizophrenia. Journal of Clinical Psychopharmacology 1990; 10(1)54–57
- Kalachnik J.E. Medication monitoring procedures: Thou shall, here's how. Pharmacotherapy and mental retardation, Gadow K.D., Poling A.G.. Taylor and Francis, London 1988; 231–269, In
- Parker G. Developmentally disabled, doubly disadvantaged. Medical Journal of Australia 1991; 155: 68–71
- Poling A., Gadow K.D., Cleary J. Drug therapy for behavior disorders: An introduction. Pergamon Press, New York 1991
- Repp A., Singh N.N. Non aversive and aversive interventions for persons with developmental disabilities. Sycamore, Sycamore, Ill. 1990
- Ryan M. Drug use in N.S.W. institutions — innovation for inertia. Australia and New Zealand Journal of Developmental Disabilities 1991; 17(2)177–181
- Sachdev P.S. Psychoactive drug use in an institution for intellectually handicapped persons. Medical Journal of Australia 1991; 155: 75–79
- Wilken P., Hudson A. Evaluation of the Behaviour Intervention Support Team Program: Formative Report No. 2. Royal Melbourne Institute of Technology, Bundoora 1992